HK Stock Market Move | ZAI LAB(09688) rose by over 7%, with significant increases in sales of core products Dingyoule and Newjoy.

ZAI LAB (09688) continues to rise by more than 7%, as of the time of writing, it has increased by 6.39% to 15.15 Hong Kong dollars, with a trading volume of 1.09 billion Hong Kong dollars. On the news front, ZAI LAB previously announced that its total revenue for the fourth quarter of 2025 was 127.6 million US dollars, a year-on-year increase of 17%; The total revenue for the full year of 2025 was 460.2 million US dollars, a year-on-year increase of 15%. UBS pointed out that ZAI LAB's fourth-quarter performance is roughly in line with expectations, with revenue increasing by 17% year-on-year to 127.1 million US dollars, slightly exceeding the bank's and market expectations. Western noted that sales of ZAI LAB's core products Dingyoule and Niuzaile have increased significantly, reaching 22.9 million US dollars (+593%) and 60.8 million US dollars (+41%) respectively. The report also mentioned that the company's core pipeline is progressing smoothly in clinical trials, with ZL-1310's global Phase III clinical research progressing rapidly, with most enrollments expected to be completed by 2026; KarXT was listed in December 2025. There will be multiple milestone events in 2026, including the updated clinical data for ZL-1310 and the potential launch of vadutuximab talirine for cervical cancer indications.